Literature DB >> 1777424

Antigen targetting with monoclonal antibodies as vectors--II. Further evidence that conjugation of antigen to specific monoclonal antibodies enhances uptake by antigen presenting cells.

S Mjaaland1, S Fossum.   

Abstract

Immunization of rats with haptenized monoclonal antibodies (mAbs) against accessory cells enhances anti-hapten antibody responses. To see whether the mAb-conjugates really targetted the antigen (hapten) to the antigen presenting cells, we have investigated the lymph node distribution of locally injected radiolabelled conjugates. Compared with control conjugates, i.e. haptenized non-binding mAbs, a much larger proportion of the specific conjugates were retained in the draining lymph nodes. Whereas control conjugates were rapidly phagocytosed and degraded by macrophages, the specific conjugates were associated with the targetted accessory cells, which were radiolabelled for extended periods. Haptenated MRC OX6 (anti-MHC class II) gave strong labelling of interdigitating cells (IDC) in the paracortex with 70% of IDC still labelled by 4 days and 15% by 16 days following injection. By Western blots intact OX6 conjugates were still detected in the draining lymph node as long as 3 days after injections, whereas control conjugates were hardly detectable even by 24 h. The findings substantiate the idea that mAbs can be exploited for vectorial transport of antigens to accessory cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1777424     DOI: 10.1093/intimm/3.12.1315

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  2 in total

1.  Anti-class II monoclonal antibody-targeted Vibrio cholerae TcpA pilin: modulation of serologic response, epitope specificity, and isotype.

Authors:  J Y Wu; R K Taylor; W F Wade
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 2.  Controlling immune responses by targeting antigens to dendritic cell subsets and B cells.

Authors:  Craig P Chappell; Natalia V Giltiay; Christiane Dresch; Edward A Clark
Journal:  Int Immunol       Date:  2013-11-27       Impact factor: 4.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.